Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Significance of re-biopsy of histological tumor samples in advanced non-small-cell lung cancer in clinical practice

Published:2018-08-29 Issue:1 Volume:24 Page:41-45
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Hotta Katsuyuki,Ninomiya Kiichiro,Ichihara Eiki,Kiura Katsuyuki

Funder

AstraZeneca

Ono Pharmaceutical

Astellas Pharma

Bristol-Myers Squibb

MSD

Lilly

Daiichi-Sankyo Pharmaceutical

Boehringer-Ingelheim

Nihon Kayaku

Taiho Pharmaceutical

Chugai Pharmaceutical

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/article/10.1007/s10147-018-1344-x/fulltext.html

Reference38 articles.

1. Hotta K, Matsuo K, Ueoka H et al (2004) Meta-analysis of randomized clinical trials comparing cisplatin to carboplatin in patients with advanced non-small-cell lung cancer. J Clin Oncol 22:3852–3859

2. Hotta K, Matsuo K, Ueoka H et al (2004) Addition of platinum compounds to a new agent in patients with advanced non-small-cell lung cancer: a literature based meta-analysis of randomised trials. Ann Oncol 15:1782–1789

3. Hotta K, Matsuo K (2007) Long-standing debate on cisplatin- versus carboplatin-based chemotherapy in the treatment of advanced non-small-cell lung cancer. J Thorac Oncol 2:96

4. Hotta K, Fujiwara Y, Matsuo K et al (2007) Recent improvement in the survival of patients with advanced non small cell lung cancer enrolled in phase III trials of first-line, systemic chemotherapy. Cancer 109:939–948

5. Hotta K, Takigawa N, Hisamoto-Sato A et al (2013) Reappraisal of short-term low-volume hydration in cisplatin-based chemotherapy: results of a prospective feasibility study in advanced lung cancer in the Okayama Lung Cancer Study Group Trial 1002. Jpn J Clin Oncol 43:1115–1123

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced non-squamous NSCLC with no actionable oncogenic driver in Spain: a cross-sectional descriptive analysis of data from the Thoracic Tumor Registry;Clinical and Translational Oncology;2024-06-11

2. First and repeat rebiopsy for detecting EGFR T790M mutation in non-small-cell lung cancer: CS-Lung-003 prospective observational registry study;Journal of Cancer Research and Clinical Oncology;2022-04-06

3. Actionable Molecular Alterations Are Revealed in Majority of Advanced Non-Small Cell Lung Cancer Patients by Genomic Tumor Profiling at Progression after First Line Treatment;Cancers;2021-12-28

4. Molecular testing and targeted therapy for non-small cell lung cancer: Current status and perspectives;Critical Reviews in Oncology/Hematology;2021-01

5. Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression;Lung Cancer;2020-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3